• Incyte Corp., of Wilmington, Del., presented further analyses from its pivotal Phase III program for Jakafi (ruxolitinib), which included data showing consistent benefit of the drug over placebo in spleen volume reduction and symptom improvement across subgroups of myelofibrosis patients, as well as an overall survival advantage. Jakafi gained approval for myelofibrosis earlier this year.